A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors

Trial Profile

A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs PLX 8394 (Primary)
  • Indications Hairy cell leukaemia; Malignant melanoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Sponsors Plexxikon
  • Most Recent Events

    • 15 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Apr 2014 Planned number of patients changed from 42 to 172 as reported by ClinicalTrials.gov record.
    • 18 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top